NASDAQ · INBS
Healthcare · Medical - Diagnostics & Research
$2.19
Down-$0.09 (-4.11%)
Updated Sep 11, 2026, 2:24 PM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
INBS closed at $2.19 after 20 trading sessions, down 27.00% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $2.24 | $2.24 | $2.11 | $2.19 | 30.37K |
| Sep 9, 2026 | $2.15 | $2.29 | $2.12 | $2.24 | 73.48K |
| Sep 8, 2026 | $2.25 | $2.29 | $2.13 | $2.15 | 69.78K |
| Sep 4, 2026 | $2.29 | $2.40 | $2.15 | $2.23 | 91.72K |
| Sep 3, 2026 | $2.47 | $2.5597 | $2.26 | $2.30 | 132.51K |
| Sep 2, 2026 | $2.44 | $2.61 | $2.30 | $2.47 | 183.69K |
| Sep 1, 2026 | $2.40 | $2.84 | $2.05 | $2.43 | 5.04M |
| Aug 31, 2026 | $2.38 | $2.41 | $2.335 | $2.40 | 24.05K |
| Aug 28, 2026 | $2.33 | $2.3996 | $2.265 | $2.36 | 16.98K |
| Aug 27, 2026 | $2.33 | $2.4135 | $2.24 | $2.27 | 21.71K |
| Aug 26, 2026 | $2.35 | $2.4799 | $2.245 | $2.26 | 45.24K |
| Aug 25, 2026 | $2.32 | $2.49 | $2.3001 | $2.36 | 58.7K |
| Aug 24, 2026 | $2.43 | $2.67 | $2.2501 | $2.50 | 215.8K |
| Aug 21, 2026 | $2.66 | $2.70 | $2.42 | $2.51 | 48.65K |
| Aug 20, 2026 | $2.62 | $2.75 | $2.60 | $2.65 | 51.38K |
| Aug 19, 2026 | $3.26 | $3.26 | $2.63 | $2.67 | 203.26K |
| Aug 18, 2026 | $3.35 | $3.36 | $3.04 | $3.22 | 79.03K |
| Aug 17, 2026 | $2.86 | $3.49 | $2.86 | $3.37 | 244.73K |
| Aug 14, 2026 | $2.94 | $3.09 | $2.63 | $2.77 | 91.01K |
| Aug 13, 2026 | $2.55 | $3.08 | $2.42 | $3.00 | 428.93K |
The latest Smart Investors Daily articles mentioning INBS.
INBS research
Company profile and research snapshot.
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company operates through new reportable segments: United Kingdom; Asia Pacific (APAC); Americas; and Rest of World, of which United Kingdom derives maximum revenue.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Feb 24, 2026
Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced a partnership with Bouygues UK, a
Benzinga · Feb 12, 2026
Intelligent Bio Solutions (NASDAQ:INBS) reported quarterly losses of $(2.82) per share. This is a 43.15 percent increase over losses of $(4.96) per share from the same period last year. The company reported $896.774
Yahoo · Feb 5, 2026
Expected record fiscal second quarter revenue increase driven by expanding customer base and strong growth across all product categories Reader sales expected to post year-over-year growth of more than 100% in fiscal Q2, expanding installed base to drive sustained recurring cartridge revenue NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions
Yahoo · Jan 28, 2026
Clinical studies designed to support FDA clearance and planned commercial launch into the world’s largest drug screening market Company anticipates full data analysis by the end of March 2026; data to be incorporated into FDA 510(k) submission package NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the commencement of its
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning INBS.
